Montelukast dicyclohexylamine salt
[CAS# 577953-88-9]

Identification

• Classification: Chemical reagent >> Organic reagent >> Amine salt (ammonium salt)
• Name: Montelukast dicyclohexylamine salt
• Synonyms: 2-[1-[[[(1R)-1-[3-[(1E)-2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropyl]acetic acid dicyclohexylamine salt
• Molecular Formula: C₃₅H₃₆ClNO₃S.C₁₂H₂₃N
• Molecular Weight: 767.50
• CAS Registry Number: 577953-88-9
• EC Number: 611-575-8
• SMILES: CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O.C1CCC(CC1)NC2CCCCC2

Safety Data

• Hazard Symbols: GHS07;GHS09 Warning
• Risk Statements: H319-H400-H410
• Safety Statements: P264+P265-P273-P280-P305+P351+P338-P337+P317-P501

Hazard Classification

Hazard	Class	Category Code	Hazard Statement
Chronic hazardous to the aquatic environment	Aquatic Chronic	1	H410
Acute hazardous to the aquatic environment	Aquatic Acute	1	H400
Eye irritation	Eye Irrit.	2	H319

Discovery and Applications

Montelukast dicyclohexylamine salt is a derivative of montelukast, a well-known leukotriene receptor antagonist used primarily in the treatment of asthma and allergic rhinitis. Montelukast works by blocking leukotrienes, chemicals that are involved in inflammatory responses and bronchoconstriction in the airways. The development of montelukast dicyclohexylamine salt represents a formulation that improves the compound’s stability and handling during the production and storage phases.

The discovery of montelukast dicyclohexylamine salt emerged from the need to optimize the physical and chemical properties of the active pharmaceutical ingredient (API), montelukast sodium. Montelukast itself is sensitive to moisture and light, which can compromise its effectiveness and shelf life. The dicyclohexylamine salt form of montelukast was introduced as a means of improving the drug's thermal stability, making it easier to handle in manufacturing environments. By forming a salt with dicyclohexylamine, the stability of montelukast is enhanced without altering its pharmacological properties.

The application of montelukast dicyclohexylamine salt is predominantly in the pharmaceutical industry, where it is used as an intermediate during the manufacturing process of montelukast formulations. This salt form is not typically used in final dosage forms (such as tablets or granules) for therapeutic use but serves as an important precursor to the final, more commonly used montelukast sodium. The stability provided by the dicyclohexylamine salt allows for better control over the crystallization process, contributing to the production of montelukast sodium with desirable particle size, purity, and overall quality.

In drug development, the exploration of various salt forms of active pharmaceutical ingredients is crucial for optimizing production efficiency, bioavailability, and stability. Montelukast dicyclohexylamine salt is an example of how alternative salt forms can enhance drug processing without affecting the drug's efficacy. This has practical implications for pharmaceutical companies seeking to scale up production and maintain the quality of montelukast over long periods of storage and transport.

Montelukast dicyclohexylamine salt’s contribution to the manufacturing process of montelukast sodium highlights its significance in the supply chain for asthma medications. As the demand for effective treatments for respiratory conditions continues to rise globally, innovations like this help ensure the reliable production and distribution of essential drugs.

References

none